Advancing the CAR-T conversation in India: Highlights from Max Cancer Congress 2026 The discussions underscored several priorities shaping the field: early patient identification and referral, effective disease management before infusion, and growing real-world evidence.

A meaningful step toward CAR-T therapy in India. NexCAR19, World's first humanized CAR-T therapy, has been administered at Command Hospital, Kolkata, to a serving soldier with relapsed/refractory B-ALL. Read more: ssbcrack.com/2026/10/command…

Real-world evidence is shaping the next chapter of CAR-T therapy in India. At the Indian Association for Cell and Gene Therapy (IACGT), our team had the opportunity to contribute to the conversation and engage with the growing body of clinical experience shaping CAR-T in India.

Could CAR-T have a greater impact when considered earlier in the treatment journey? In the latest edition of "Learn from the Experts", Dr. Esha Kaul, shares her perspective on the role of CAR-T in earlier lines of treatment. #LearnFromTheExperts #CARTCellTherapy #ImmunoACT

When should the conversation around CAR-T therapy begin? In this video, Dr Rayaz Ahmed, Vice Chairman, Department of Hematology & BMT, Max Healthcare, shares his perspective on bringing CAR-T into the conversation earlier in the patient journey. #NexCAR19 #CARTCellTherapy

Early referral can make a meaningful difference in the CAR-T journey. Dr. Anusha Swaminathan shares why timely evaluation matters in relapsed or refractory B-cell malignancies — allowing time for assessment, planning and risk management. Read the article aninews.in/news/business/why…

A proud moment for ImmunoACT! Our Founder, Dr. Rahul Purwar, has been honoured with the Prof. S. L. Mehndiratta Award for Breakthrough Research in Science & Engineering (2026). A well-deserved recognition of his pioneering work in CAR-T cell therapy and cancer immunology.

We're grateful to the @EduMinOfIndia , and @BharatInnovMoE for the opportunity to showcase our work at BRICS 2026, Bharat Mandapam, New Delhi — as one of 37 teams representing India's frontier tech sectors. Proud to be part of India's innovation story.

Another milestone for CAR-T therapy in India. For a young patient battling relapsed refractory B-cell ALL, this milestone is a reminder of what innovation in cancer care can make possible — new hope, new possibilities and new beginnings. Congratulations to the entire team.

From an indigenous innovation to real-world patient outcomes. Our 250-patient, 56-centre study of NexCAR19, published in @BloodCancerJnl , is now featured by @NewIndianXpress A meaningful milestone for India's CAR-T journey — and, most importantly, for expanding access to advanced cancer care. Read the full article here: newindianexpress.com/india/2… #NexCAR19 #CART #CellTherapy #RealWorldEvidence #MadeInIndia

This Independence Day, we celebrate the India we are building together. An India where innovation moves forward, compassion remains at the heart of progress, and every life is valued equally. As our country continues to grow in science, healthcare, and technology, may that progress reach those who need it most. May we continue to build a healthier India—one where access to better care is not a privilege, but a possibility for every patient. 🇮🇳 Happy Independence Day! 🇮🇳 #IndiaIndependenceDay #Healthcare #ImmunoACT #Innovation

Can advanced cell therapies be delivered at scale without compromising quality? That's one of the key questions explored in Dr. Atharva Karulkar's latest interview with @Citeline . Drawing on the largest real-world CAR-T dataset from India, the discussion explores the science, manufacturing, logistics, and clinical outcomes behind NexCAR19, and why scalable access may become just as important as scientific innovation itself. Some of the key insights from the conversation include: • A 98% manufacturing success rate and a median vein-to-vein time of 29 days, enabled by a centralized manufacturing model and real-time logistics tracking. • Real-world outcomes from 250 patients demonstrating efficacy comparable to globally approved CAR-T therapies in both leukemia and lymphoma. • An approach to improving patient access through outcome-based financing and 0% EMI options, while working towards broader government and insurance inclusion. • ImmunoACT's vision to expand manufacturing capacity, strengthen its global footprint, and make equitable access to CAR-T therapy a reality for patients beyond India. Read the full interview: insights.citeline.com/scrip/… #biotechology #bloodcancer #ImmunoACT

What does a difficult-to-treat, real-world B-cell Non-Hodgkin Lymphoma (B-NHL) population actually look like? In our previous publication spotlight, we explored the baseline characteristics of patients with relapsed/refractory B-ALL. This time, we turn to the 145 patients with relapsed/refractory B-NHL included in our study, published in Nature Portfolio's Blood Cancer Journal. Like the B-ALL cohort, these patients reflect the realities of treating relapsed/refractory disease in routine clinical practice — physicians managing aggressive disease, extensive prior treatment histories, and limited therapeutic options. Disease characteristics: 🔹 75% had primary refractory disease or an early relapse — an aggressive disease biology 🔹 80% had DLBCL & HGNHL histology — Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma, the most aggressive B-NHL subtypes 🔹 37% presented with bulky disease (tumour bulk ≥5 cm) prior to leukapheresis — associated with higher disease burden and treatment complexity 🔹 55% had extranodal disease — lymphoma involvement beyond the lymph nodes, reflecting more advanced disease Treatment history: 🔹 83% had received 2+ prior lines of therapy — a heavily pretreated cohort NexCAR19 was evaluated in this real-world, difficult-to-treat B-NHL population — representative of the patients clinicians encounter in everyday practice. Read the full publication for complete patient characteristics, study methodology, and real-world efficacy and safety outcomes: doi.org/10.1038/s41408-026-0… Disclaimer: This post is for educational purposes. #biotechnology #bloodcancer #ImmunoACT

What does a difficult-to-treat, real-world B-cell Acute Lymphoblastic Leukemia (B-ALL) population actually look like? Our study, published in @NaturePortfolio 's Blood Cancer Journal, reports baseline characteristics of 105 patients with relapsed/refractory B-ALL — drawn from a broader cohort of 250 patients — prior to treatment with NexCAR19 — the world's first humanized, and India's first, CAR-T cell therapy. We're sharing a look at that data here: a heavily pretreated, real-world population reflecting the challenges physicians face in routine practice. Disease burden: • More than half of patients had primary refractory disease or an early relapse — a subgroup historically associated with limited treatment options and poor prognosis • 35% had high-blast leukemia (≥5% blasts) prior to leukapheresis, indicating clinically active disease at the time of treatment • 2 out of 3 patients had Ph-like or Philadelphia chromosome-negative (Ph-ve) B-ALL — subtypes that lack the BCR-ABL1 alteration targeted by tyrosine kinase inhibitors in Ph-positive disease, making them harder to treat with standard therapy and more prone to relapse • 10% had CNS involvement before leukapheresis, adding further clinical complexity Treatment history: • 3 in 4 patients had received two or more prior lines of therapy • 34% had prior exposure to inotuzumab, reflecting a cohort already exposed to contemporary treatment approaches before CAR-T Together, these characteristics define the real-world clinical context in which NexCAR19 was evaluated — a diverse, heavily pretreated population, not a curated trial cohort. Read the full paper to see how NexCAR19 delivered efficacy outcomes while also providing a favorable safety profile in ALL. doi.org/10.1038/s41408-026-0… How does this profile compare to the B-ALL patients you encounter — in the clinic or in your own research? We would love to know your perspective. #biotechnology #bloodcancer #ImmunoACT

Developing NexCAR19, India's first indigenous CD19 CAR-T therapy was a scientific milestone. Delivering it to patients across the country proved just as demanding — and entirely different. For a patient with relapsed blood cancer, access to treatment shouldn't depend on how far they live from a manufacturing site. Yet without the right infrastructure, that distance often determines who gets treated in time. So, we set out to build a system to close that gap: a Centralized Coordinating Unit in Mumbai designed to deliver the same standard regardless of geography. Our new publication in Nature Portfolio's Blood Cancer Journal presents the real-world data behind it: across 250 patients treated at 56 centres nationwide, ImmunoACT achieved a 98% manufacturing success rate — demonstrating that consistent, high-quality CAR-T care can be delivered reliably, irrespective of geography. We're proud of what our team has built, and of what it means for patients everywhere who deserve access to the best that science can offer. Read the publication: doi.org/10.1038/s41408-026-0… Disclaimer: This post is for educational purposes.

India's First Real-World Evidence for CAR-T Therapy, Now Published We're proud to announce a landmark milestone — the publication of the first real-world evidence (RWE) on CAR-T therapy from India, now published in Blood Cancer Journal (Nature Portfolio | Impact Factor: 13.8), one of the world's leading hematology journals. This study centres on NexCAR19, India's first indigenously developed CAR-T cell therapy. Drawing on real-world data from 250 patients treated across 56 centres, this is the first multicentre evaluation of CAR-T therapy in routine clinical practice in India. It marks a defining moment for cell therapy in the country: evidence that CAR-T can be delivered at scale, across diverse centres, with outcomes captured in real-world settings rather than the controlled environment of a trial. To the authors and contributors — thank you. This achievement belongs to the entire community behind it. Our deepest gratitude to the study authors, and to the clinicians, collaborating institutions, healthcare professionals, and researchers across all 56 centres whose expertise and dedication made this work possible. Above all, we thank the patients and caregivers who placed their trust in this therapy. Over the coming weeks, we'll share key findings from the study and what they mean for the evolving landscape of CAR-T therapy in India. For more information, visit: doi.org/10.1038/s41408-026-0… Disclaimer: This post is for educational purposes.

We thank @mygovindia for highlighting NexCAR19™ and India's growing journey towards healthcare self-reliance through indigenous innovation. NexCAR19™ is India's first indigenous CAR-T cell therapy for cancer and a testament to the country's ability to develop world-class, cutting-edge therapies that address critical healthcare needs. Developed by ImmunoACT, NexCAR19™ is helping make advanced cell and gene therapy more accessible and affordable for patients battling relapsed or refractory B-cell malignancies. Driven by a vision to bring transformative innovations from the laboratory to the patient's bedside, ImmunoACT has worked to ensure that CAR-T cell therapy is not just a scientific breakthrough, but a realistic treatment option for patients across India. Today, NexCAR19™ has treated over 750 patients, offering renewed hope to individuals and families facing blood cancers. This milestone reflects the dedication of scientists, clinicians, researchers, healthcare partners, and patients who have collectively contributed to advancing cancer care in India. Together, we are building a future where life-saving innovations are developed in India and made accessible to those who need them most. 🔗 View the MyGov India post: instagram.com/p/DZjTZ1xEWFZ/… #ImmunoACT #NexCAR19 #CARTCellTherapy #MadeInIndia #CancerCare #HealthcareInnovation #CellAndGeneTherapy #AtmanirbharBharat #BloodCancer #Biotechnology #IndiaInnovation @purwarrahul2 @atharvak03 @sarya3 @shreshthashah97 @Dr_SushantK @mygovindia @BIRAC_2012 @narendramodi @TataMemorial @EduMinOfIndia @HealthCareGov